BACKGROUND: The need to have a variety of tools to deal with end-stage heart failure (ES-HF), along with the limited heart transplantation availability encouraged us to create a pilot Left ventricular assist device (LVAD) program in a public health care system hospital in Chile. METHODS: A retrospective analysis of the first nine patients of an ongoing LVAD program initiated on August 2013 was performed, completing an average of 30 months of follow-up. The most important events regarding to morbidity and mortality are described. RESULTS: Nine patients with ES-HF underwent LVAD implantation surgery; one of them died 23 days after surgery and another died after 11 months. One patient successfully underwent heart transplantation after 16 months of HeartWare ventricular assist device (HVAD) support; the other six patients remain in the program and have an average follow-up of 846 days at the time of this study (range, 23-1,481 days). The survival rate at 6, 12 and 18 months follow-up was 89%, 78% and 78% respectively. CONCLUSIONS: This new pioneering LVAD program in Chile has been successful and now constitutes a vital adjunct to all who work in heart transplantation and ES-HF programs. It offers an effective therapeutic alternative when there is a severe donor shortage, in cases of atypical blood types, emergencies, exceptional cases with contraindication for heart transplantation or when there is important donor-receiver size mismatch.
BACKGROUND: The need to have a variety of tools to deal with end-stage heart failure (ES-HF), along with the limited heart transplantation availability encouraged us to create a pilot Left ventricular assist device (LVAD) program in a public health care system hospital in Chile. METHODS: A retrospective analysis of the first nine patients of an ongoing LVAD program initiated on August 2013 was performed, completing an average of 30 months of follow-up. The most important events regarding to morbidity and mortality are described. RESULTS: Nine patients with ES-HF underwent LVAD implantation surgery; one of them died 23 days after surgery and another died after 11 months. One patient successfully underwent heart transplantation after 16 months of HeartWare ventricular assist device (HVAD) support; the other six patients remain in the program and have an average follow-up of 846 days at the time of this study (range, 23-1,481 days). The survival rate at 6, 12 and 18 months follow-up was 89%, 78% and 78% respectively. CONCLUSIONS: This new pioneering LVAD program in Chile has been successful and now constitutes a vital adjunct to all who work in heart transplantation and ES-HF programs. It offers an effective therapeutic alternative when there is a severe donor shortage, in cases of atypical blood types, emergencies, exceptional cases with contraindication for heart transplantation or when there is important donor-receiver size mismatch.
Authors: David L Joyce; Robert E Southard; Guillermo Torre-Amione; George P Noon; Geoffrey A Land; Matthias Loebe Journal: J Heart Lung Transplant Date: 2005-09-15 Impact factor: 10.247
Authors: Oneglio Pedemonte; Andrés Vera; Jan D Schmitto; Sebastián V Rojas; Axel Haverich; Lorenzo Merello; Manuel Novajas; Fernando Aranda; Julio Ibarra; José A Muñoz; Javier Alburquerque; Rienzi Díaz; Ernesto Aranguiz-Santander Journal: Rev Med Chil Date: 2014-07 Impact factor: 0.553
Authors: Jan D Schmitto; Daniel Zimpfer; Arnt E Fiane; Robert Larbalestier; Steven Tsui; Paul Jansz; Andre Simon; Stephan Schueler; Martin Strueber Journal: Eur J Cardiothorac Surg Date: 2016-07-13 Impact factor: 4.191
Authors: Tim Lahm; Charles A McCaslin; Thomas C Wozniak; Waqas Ghumman; Yazid Y Fadl; Omar S Obeidat; Katie Schwab; Daniel R Meldrum Journal: J Am Coll Cardiol Date: 2010-10-26 Impact factor: 24.094
Authors: Sebastian V Rojas; Jasmin S Hanke; Murat Avsar; Philipp R Ahrens; Ove Deutschmann; Kirstin A Tümler; Aitor Uribarri; Sara Rojas-Hernández; Pedro L Sánchez; José M González-Santos; Axel Haverich; Jan D Schmitto Journal: Rev Esp Cardiol (Engl Ed) Date: 2017-06-20
Authors: F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen Journal: Lancet Date: 2002-07-20 Impact factor: 79.321
Authors: Jasmin S Hanke; Sebastian V Rojas; Tomislav Cvitkovic; Bettina Wiegmann; Alexander Horke; Gregor Warnecke; Axel Haverich; Jan D Schmitto Journal: Interact Cardiovasc Thorac Surg Date: 2017-10-01
Authors: Thibault Schaeffer; Otmar Pfister; Constantin Mork; Paul Mohacsi; Florian Rueter; Simon Scheifele; Anne Morgen; Urs Zenklusen; Thomas Doebele; Markus Maurer; Joachim Erb; Jens Fassl; Nadine Cueni; Martin Siegemund; Hans Pargger; Brigitta Gahl; Stefan Osswald; Friedrich Eckstein; Martin Grapow Journal: J Cardiothorac Surg Date: 2021-03-31 Impact factor: 1.637